TerminatedPhase 2

A Placebo-controlled Study of Volixibat in Subjects With Elevated Serum Bile Acids Associated With Intrahepatic Cholestasis of Pregnancy (OHANA)

Stopped: Due to company's assessment of enrollment feasibility.

United States4 participantsStarted 2021-01-04

Plain-language summary

Part 1 is an open-label randomized study of volixibat in patients with Intrahepatic Cholestasis of Pregnancy (ICP) and elevated serum bile acid concentrations (sBA) to evaluate safety and tolerability of two doses of volixibat. Part 2 is a double-blind, placebo controlled, study designed to evaluate the safety and efficacy of a selected volixibat dose.

Who can participate

Age range18 Years – 45 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Female aged ≥18 and ≤45 years with a viable pregnancy.
✓. Provide signed informed consent as described in the protocol and willing to comply with all study visits and requirements.
✓. Diagnosis of ICP.
✓. (Part 2 only) Qualified level of pruritus associated with ICP, during screening.

Exclusion criteria

✕. At the time of either the screening or baseline visit, decision has already been made to deliver within the next 7 days, for any indication.
✕. Known non-reassuring fetal status based upon antepartum testing (e.g., NST/CTG or BPP) at or within 7 days before the baseline visit.
✕. Known fetal anomaly likely to result in intrauterine fetal demise or neonatal death within the first 30 days of life.
✕. Participating in another ongoing interventional clinical study at screening or planning to participate in another contemporaneous interventional clinical study while participating in this study.

What they're measuring

Assess the Safety and Tolerability of Volixibat in Participants With ICP

Timeframe: Through to end of treatment, up to 21 weeks

Trial details

NCT IDNCT04718961

SponsorMirum Pharmaceuticals, Inc.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2022-12-07

Results submitted2023-11-30

View on ClinicalTrials.gov More Intrahepatic Cholestasis of Pregnancy trials